Novo Nordisk's CagriSema optimism collides with an investor trust crisis
CEO Mike Doustdar touts a timely FDA approval for CagriSema, but an 8% stock slide shows confidence is the harder thing to manufacture.
Nov 4, 20264 views
Pharmaceuticals
Gut-Repairing Drug Reverses Severe Fatty Liver Disease in Animal Tests
A repurposed asthma compound and a UConn-patented candidate spotlight the gut-liver axis, as GLP-1 obesity drugs win fatty liver approvals in India and China
Oct 17, 20264 views
Hundreds of Lawsuits Allege GLP-1 Drugs Like Ozempic Caused Blindness and Pancreatitis
As courts weigh claims against Novo Nordisk and Eli Lilly, scant safety data leaves doctors, patients and juries unable to say how often serious harm occurs.
Oct 10, 20265 views
JAMA Study: Drug Patent Thickets Tripled Since 1990 as Congress Weighs Insulin Reform
Small-molecule medicines averaged 6.9 patents apiece by 2019, up from 2.1 in 1990, fueling calls on Capitol Hill to rein in Big Pharma's monopolies.
Sep 29, 20263 views
Tirzepatide May Burn Calories via Brown Fat, Study Finds; Forbes Explains Drug Differences
New mouse research suggests Mounjaro and Zepbound do more than suppress appetite, while consumer coverage focuses on distinguishing the two brands.
Sep 26, 20263 views
Trump's FDA Nominee Sidesteps Senators on Vaccines, Abortion Pill, and Whether the President Can Be Wrong
Heidi Overton affirmed that the MMR vaccine and mifepristone are safe, but spent nearly two hours refusing to answer harder questions about pushback and birth control.
Sep 26, 20263 views
GLP-1 Drugs in Children Linked to Nutritional Deficiencies—and a Rare Brain Disorder Signal
Nearly 1 in 6 young patients on Ozempic, Saxenda and similar drugs developed a deficiency within a year—even as other research flags brain risks.
Sep 24, 20264 views
Ozempic's Active Ingredient Extended Lifespan in Mice, Hinting at a New Way to Slow Aging
Semaglutide improved memory, muscle function and blood sugar in older mice—and its benefits exceeded those of calorie restriction alone, prompting human trials.
Sep 12, 20262 views
Semaglutide drugs Ozempic/Wegovy linked to fewer asthma attacks and COPD flare-ups
Real-world study shows GLP-1 medications may cut asthma attacks by 40% and COPD exacerbations by 20%, expanding their potential reach beyond diabetes and weight loss.
Sep 9, 20263 views
Ozempic’s Hidden Potential: Bipolar Disorder Hospitalization Risk Drops, but Safety Debates Persist
Swedish study of 15,000 patients finds semaglutide linked to 21% fewer psychiatric admissions; psychiatrists and lawsuits highlight mental health risk concerns.
Sep 8, 20263 views
Page 1Next